# Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Oral Doses of BI 1021958 in Otherwise Healthy Controlled Asthmatic Subjects

> **NCT01629849** · PHASE1 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 84 (actual)

## Conditions studied

- Healthy
- Asthma

## Interventions

- **DRUG:** Placebo to BI 1021958 qd
- **DRUG:** BI 1021958 bid
- **DRUG:** Placebo to BI 1021958 bid
- **DRUG:** BI 1021958 qd

## Key facts

- **NCT ID:** NCT01629849
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-07
- **Primary completion:** 2012-12
- **Final completion:** 2012-12
- **Target enrollment:** 84 (ACTUAL)
- **Last updated:** 2013-05-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01629849

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01629849, "Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Oral Doses of BI 1021958 in Otherwise Healthy Controlled Asthmatic Subjects". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01629849. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*